Enveric Biosciences, Inc.
NASDAQ · us_market
No AI insight generated yet for this ticker.
Enveric Biosciences, Inc., a biotechnology company, focuses on the development of small molecule neuroplastogenic therapeutics that address unmet needs in psychiatric and neurological disorders in the United States. Its lead drug candidate is EB-003, a novel derivative of DMT in preclinical development for mental health indications. The company also develops EVM401 series comprising novel phenylalkylamines and indolethylamines, as well as mescaline-derived compounds to target addiction and neuropsychiatric disorders; and Psybrary, a proprietary library. Enveric Biosciences, Inc. is headquartered in Cambridge, Massachusetts.
| Report Date | EPS Estimate | EPS Actual | Surprise |
|---|---|---|---|
| 2025-03-28 | -2.76 | -2.03 | +26.38% |
| 2024-11-14 | -93.60 | -43.20 | +53.85% |
| 2024-08-12 | -99.00 | -45.00 | +54.55% |
| 2024-05-15 | -139.50 | -109.80 | +21.29% |
| 2024-03-26 | -314.10 | -191.31 | +39.09% |
| 2023-11-13 | -376.20 | -287.12 | +23.68% |
| 2023-08-11 | -117.00 | -450.42 | -284.98% |
| 2023-05-15 | -630.00 | -415.80 | +34.00% |
| 2023-03-31 | -525.60 | -344.11 | +34.53% |
| 2022-11-14 | -720.00 | -582.21 | +19.14% |
| 2022-08-12 | -675.00 | -818.08 | -21.20% |
| 2022-05-13 | -1080.00 | -990.00 | +8.33% |
| 2022-03-31 | -1440.00 | -15570.00 | -981.25% |
| 2021-11-15 | -1260.00 | -1080.00 | +14.29% |
| 2021-08-06 | -1575.00 | -1800.00 | -14.29% |
| 30d | 90d | YTD | 1y | |
|---|---|---|---|---|
| ENVB | -42.36% | +9.52% | -36.64% | -83.76% |
| XLV | +2.97% | -4.64% | -3.44% | +12.69% |
| Alpha (stock − sector) | -45.33% | +14.16% | -33.20% | -96.45% |